ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today ...

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early ...

Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE)-- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s ...

ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...

ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study The challenge of focusing only on erectile function is ...

ProMIS Neurosciences Inc. PMN shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), ...

Phase 1b trial in Alzheimer’s disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled PMN310 continues to demonstrate a favorable safety profile On track to report 6-month interim data in Q2 ...

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.

Proceeds expected to enable completion of ProMIS’ landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026; 12-month top-line data ...